

Roche's Tecentriq to receive FDA priority review

07 May 2018 | News

The review would be to approve the use of Tecentriq, with Avastin and chemotherapy, in initial treatment of NSCLC



Roche Holding AG has been granted a priority review for its drug Tecentriq, for the first-line treatment of a type of lung cancer, by the U.S. Food and Drug Administration.

Tecentriq is currently FDA approved for the treatment of patients with metastatic non-squamous non-small cell lung cancer, or NSCLC. Roche says the FDA review would be for the use of Tecentriq in combination with Avastin and chemotherapy after phase 3 trial results showed potential to provide significant survival benefit in the initial treatment of NSCLC.